Vaccines & Disease · Shingles

Herpes Zoster (Shingles) & Shingles Vaccine Quick Facts

3 min read
01

Shingles

  • Herpes zoster (shingles) is a viral infection caused by the varicella zoster (chicken pox) virus.1Shingles involves inflammation of the nerves and a very painful blistering skin rash that typically lasts two to four weeks.2Herpes zoster is not caused by herpes simplex types 1 and 2 associated with cold sores and sexually transmitted genital herpes.3
  • Symptoms of shingles include pain, itching or tingling of areas of the skin, usually on the trunk of the body, along with fever, headache, chills and an upset stomach.4Complications of shingles include postherpetic neuralgia (chronic nerve pain), loss of vision, hearing problems, brain inflammation (encephalitis), Bell’s palsy, pneumonia and, rarely, death.5
  • Individuals suffering with shingles cannot transmit shingles to others. However, someone who has never had chickenpox or the chickenpox vaccine can get chickenpox from a person with shingles. This is believed to be from direct contact with the shingles lesions.6
  • Herpes zoster is most common in individuals over 50 years of age;7 however, individuals who are immunocompromised or who take medications that suppress the immune system are at higher risk.8
  • Treatment with antivirals may shorten the time it takes to recover from shingles.9Over-the-counter or prescription pain medication may help to relieve pain and calamine lotion, colloidal oatmeal baths, and wet compresses may assist with itching.10
02

Shingles Vaccine

  • There are two vaccines licensed in the U.S.: Zostavax, a live virus vaccine, licensed in 2006 and manufactured by Merck11 and SHINGRIX, a genetically engineered recombinant, adjuvanted vaccine, licensed in 2017 and manufactured by GlaxoSmithKline Biologicals.12Zostavax was discontinued in the U.S. in November 2020.13 Shingles vaccination is currently recommended for all persons age 50 and older and for individuals 19 years and older who are immunocompromised.14
  • Reported complications from SHINGRIX vaccine include swelling, pain and redness at the injection site, headache, muscle pain, shivering, fatigue, gout (including gouty arthritis), optic ischemic neuropathy and Guillain-Barré syndrome.15 Reported complications from Zostavax vaccine include local swelling, pain and redness at injection site; zoster-like skin rash, headache, joint pain, muscle pain, fever, abnormally swollen glands, and hypersensitivity reactions including anaphylaxis (shock).16
  • Zostavax vaccine effectiveness is reported to be about 51 percent17 while SHINGRIX is reported to be over 90 percent effective.18 There is no available test to determine immunity to shingles and long-term vaccine effectiveness is unknown.19
  • Zostavax vaccine contains live attenuated varicella zoster virus and vaccine strain virus transmission of chickenpox from the vaccinated to susceptible individuals has been reported.20Mass use of chickenpox vaccine by children in the U.S. since 1995 has limited natural boosting of varicella zoster immunity in the adult population and there has been a significant increase in cases of herpes zoster among adults.2122
  • Using the MedAlerts search engine, as of January 2, 2026, there have been 134,663 reports of shingles vaccine reactions, hospitalizations, injuries and deaths following shingles vaccinations made to the federal Vaccine Adverse Event Reporting System (VAERS), including 585 related deaths, 6,013 hospitalizations, and 3,078 related disabilities.

NVIC “Quick Facts” is not a substitute for becoming fully informed about Shingles and the Shingles vaccine. NVIC recommends consumers read the more complete information contained in the vaccine manufacturer product information inserts, the links provided in our Quick Facts, and speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child.

03

Product Inserts & Resources

Food & Drug Administration (FDA)

Centers for Disease Control (CDC)

04

Vaccine Reactions

Reporting a Vaccine Reaction

Since 1982, NVIC has operated a Vaccine Reaction Registry, which has served as a watchdog on VAERS. Reporting vaccine reactions to VAERS is the law. If your doctor will not report a reaction, you have the right to report a suspected vaccine reaction to VAERS.

Vaccine Reaction Symptoms & Ingredients

Our Ask 8, If You Vaccinate webpage contains vaccine reaction symptoms and more.

Bottom Line
Vaccination is not a one-size-fits-all medical intervention. Before you take a risk, find out what it is.

Search for Vaccine Reactions

NVIC hosts MedAlerts, a powerful VAERS database search engine. MedAlerts examines symptoms, reactions, vaccines, dates, places, and more.

IMPORTANT NOTE: NVIC encourages you to become fully informed about Shingles and the Shingles vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.

References
  1. 1US Centers for Disease Control and Prevention. Clinical Overview. Oct. 5, 2020.
  2. 2US Centers for Disease Control and Prevention. Signs and Symptoms. July 1, 2019.
  3. 3Mayo Clinic. Shingles. Aug. 20, 2022.
  4. 4US Centers for Disease Control and Prevention. Signs and Symptoms. July 1, 2019.
  5. 5US Centers for Disease Control and Prevention. Complications. July 1, 2019.
  6. 6US Centers for Disease Control and Prevention. Transmission. July 1, 2019.
  7. 7Nichols H. What is Shingles? Medical News Today. Sept. 21, 2021.
  8. 8US Centers for Disease Control and Prevention. About Shingles (Herpes Zoster). July 1, 2019.
  9. 9Janniger C. Herpes Zoster Medication. Medscape. July 21, 2021.
  10. 10US Centers for Disease Control and Prevention. Treating Shingles. Dec. 9, 2020.
  11. 11Merck & Co. Package Insert – Zostavax (Frozen). U.S. Food and Drug Administration. Dec. 26, 2019.
  12. 12GlaxoSmithKline Biologics. Package Insert – SHINGRIX. U.S. Food and Drug Administration. Aug. 2, 2021.
  13. 13US Centers for Disease Control and Prevention. What Everyone Should Know About Zostavax. Oct. 5, 2020.
  14. 14Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR. Jan. 21, 2022; 71(3);80–84.
  15. 15GlaxoSmithKline Biologics. Package Insert – SHINGRIX. U.S. Food and Drug Administration. Aug. 2, 2021.
  16. 16Merck & Co. Package Insert – Zostavax (Frozen). U.S. Food and Drug Administration. Dec. 26, 2019.
  17. 17US Centers for Disease Control and Prevention. What Everyone Should Know About Zostavax. Oct. 5, 2020.
  18. 18US Centers for Disease Control and Prevention. How Well Does Shingrix Work? Jan. 25, 2018.
  19. 19Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR. Jan. 26, 2018; 67:103–108.
  20. 20Merck & Co. Package Insert – Zostavax (Frozen). U.S. Food and Drug Administration. Dec. 26, 2019.
  21. 21Goldman GS. Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine. March 2013; 31(13): 1680–1694.
  22. 22Goldman GS. Insights on the Impact of External and Internal Boosting on Varicella-Zoster Virus Reactivation Based on Evidence From the First Decade of the United States Universal Varicella Vaccination Program. Cureus. Aug. 6, 2021.
Select disease / vaccine